Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Pediatric Hematology/Oncology
•
Hodgkin Lymphoma
•
Hematology
Does the preferred regimen for advanced stage Nodular lymphocyte predominant Hodgkin lymphoma differ in pediatrics from adult treatment?
Related Questions
How would you counsel patients with personal or family histories of autoimmune disease on immune checkpoint inhibitor therapy for Hodgkin lymphoma?
What adverse events would make you switch off nivo + AVD therapy and to what second line therapy in patients with Hodgkin Lymphoma?
For patients with Stage IIIB or IV HD flowing Bv-AVEPC with initial large mediastinal adenopathy, how can we avoid ISRT?
How would you proceed for a patient who has completed therapy for classic Hodgkin lymphoma with overall great disease response, but with new FDG avid lymph node on PET that is not amenable to biopsy?
What factors should be considered when deciding whether to omit radiation in pediatric/AYA patients receiving N+AVD, particularly regarding long-term outcomes and second malignancy risks?
What is the optimal timing for PET/CT to assess disease and treatment response with nivo + AVD?
Would you change therapy for a CML patient in hematologic remission on imatinib found with positive qualitative BCR-ABL1 for the p230 protein?
What is your standard for monitoring triglyceride level during therapy for ALL, particularly in regards to receiving pegaspargase?
What is your standard diagnostic workup to confirm GVHD in a patient post-BMT with skin rash and jaundice?
What are the treatment options for relapsed T-ALL in a patient who was nonadherent with AALL and hyper-CVAD regimens?
